Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.48 |
| ▸ | ME2 | P23368 | 1/20 | 0.44 |
| ▸ | ME1 | P48163 | 1/20 | 0.44 |
| ▸ | ME3 | Q16798 | 1/20 | 0.44 |
| ▸ | IDH2 | P48735 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1410143 | 0.89 | NOTUM (0.63) | NOTUMCA12CA2CA9CYP3A4 | |
| SCHEMBL13158337 | 0.86 | NOTUM (0.44) | NOTUMCA12CA2CA9CYP3A4 | |
| SCHEMBL28650484 | 0.82 | CA12 (0.65) | NOTUMCA12CA2CA9CYP3A4 | |
| SCHEMBL2093736 | 0.81 | NOTUM (0.54) | NOTUMCA12CA2CA9CYP3A4 | |
| SCHEMBL16285249 | 0.81 | HRH3 (0.52) | CA12CA2CA9HRH3ALDH1A1 | |
| SCHEMBL1704614 | 0.81 | NOTUM (0.54) | NOTUMCA12CA2CA9CYP3A4 | |
| SCHEMBL2056103 | 0.81 | NOTUM (0.54) | NOTUMCA12CA2CA9CYP3A4 | |
| SCHEMBL25026058 | 0.81 | NOTUM (0.53) | NOTUMCA12CA2CA9CYP3A4 | |
| SCHEMBL2166648 | 0.81 | HRH4 (0.56) | NOTUMCA12CA2CA9CYP3A4 | |
| SCHEMBL25198162 | 0.80 | MAOB (0.74) | MEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CENTAURUS THERAPEUTICS (US) | 2026-03-12 | — | — | US | disclosed |
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2025-03-11 | — | — | US | disclosed |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| CN-111787916-B | Dihydroceramide desaturase inhibitors for treating diseases | 森陶鲁斯治疗公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20230089247-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | ZYDUS LIFESCIENCES LIMITED (IN) | 2023-03-23 | — | — | US | disclosed |
| US-11597715-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2023-03-07 | — | — | US | disclosed |
| US-11597715-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2023-03-07 | — | — | US | disclosed |
| EP-4081509-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | Zydus Lifesciences Limited (IN) | 2022-11-02 | — | — | EP | disclosed |
| CN-114901640-A | Novel compounds useful for the treatment of dyslipidemia | 兹杜斯生命科学有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1204665-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | Millennium Pharmaceuticals, Inc. (US) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001009138-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| US-5852040-A | Neuroprotective 3,4-dihydro-2(1H)-quinolone compounds | PFIZER INC. (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0828513-A2 | COMBINATIONS FOR THE TREATMENT OF PARKINSONISM CONTAINING SELECTIVE NMDA ANTAGONISTS | PFIZER INC. (US) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996037226-A2 | COMBINATIONS FOR THE TREATMENT OF PARKINSONISM CONTAINING SELECTIVE NMDA ANTAGONISTS | PFIZER INC. (US) | 1996-11-28 | — | — | WO | disclosed |
| US-4166853-A | Antihypertensive 7-trifluoromethyl-4-aminoquinolones | THE UPJOHN COMPANY (US) | 1979-09-04 | — | — | US | disclosed |
| US-4016281-A | Tetralone and indanone compounds | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597715-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, SMPD1, ASAH1 | NOTUM 148/4885CA12 3943/4885CA2 2595/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | NOTUM 3827/4885CA12 1998/4885CA2 1853/4885 |
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CERS2, DEGS1, CERT1 | NOTUM 131/4885CA12 3456/4885CA2 1234/4885 |
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, SMPD1, ASAH1 | NOTUM 148/4885CA12 3943/4885CA2 2595/4885 |
| US-20230089247-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | PCSK9, CETP, LCAT | NOTUM 149/4885CA12 4441/4885CA2 3505/4885 |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CERS2, SMPD1, ASAH1 | NOTUM 148/4885CA12 3943/4885CA2 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.